DelSiTech Ltd (infodelsitech.com), Jan 4th 2018
DelSiTech Ltd, a Finnish drug delivery technology and development company announced today that Professor Reijo Salonen has been appointed to its Board of Directors, effective as of January 1, 2018.
Reijo Salonen, MD, PhD, a specialist in neurology, is the former Senior Vice President, Head of R&D and Chief Medical Officer of the mid-sized private Finnish pharma company Orion Pharma (from 2006 to 2017). Prior to that, Reijo Salonen had a position at Pfizer as Vice President and Worldwide Therapeutic Area Head in Neurosciences, and at GlaxoSmithKline as Vice President, Clinical Development & Medical Affairs for Neurology, Psychiatry and Gastrointestinal therapeutic areas. Besides his professional career, Professor Salonen has had numerous Board and Committee positions in international and Finnish medical, scientific and industry organizations over the last 15 years.
“We are very pleased to welcome Reijo Salonen to DelSiTech,” said Dr. Örjan Andersson, Chairman of DelSiTech’s Board of Directors. “Professor Salonen has an extensive international track record in pharma industry and a deep understanding in drug discovery, clinical development and regulatory affairs. He brings to our Board a considerable knowledge of the drug development processes and strategic vision that will help DelSiTech to grow faster.”
“DelSiTech has a unique and exciting technology that I believe allows the development of novel controlled release drugs to satisfy many unmet medical needs,” said Prof. Reijo Salonen. “I’m confident that the company’s prospects are excellent, and I look forward to working with the team to take more products into clinical development.”